Update on Bracknor financing

RNS Number : 3262G
Advanced Oncotherapy PLC
26 May 2017
 

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Update on Bracknor financing

 

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the Company has drawn down the third tranche of £1.3 million (less 5%, in accordance with terms for receipt of 95% of nominal value of each tranche), for proceeds of £1.235 million.

 

 

 

Advanced Oncotherapy Plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 20 3617 8728

Nicolas Serandour, CEO




Stockdale Securities (Nomad & Joint Broker)


Antonio Bossi / David Coaten

Tel: +44 20 7601 6100



Stifel Nicolaus Europe (Joint Broker)


Jonathan Senior / Ben Maddison

Tel: +44 20 7710 7600



Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

 

 

About Advanced Oncotherapy plc www.avoplc.com

 

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCPGUWWAUPMUAQ
UK 100

Latest directors dealings